The oral and extended-release injectable formulations of naltrexone showed similar effectiveness in reducing heavy-drinking days when initiated in a hospital setting for patients with alcohol use disorder (AUD), a randomized trial has found. The study also found no significant between-group difference in acute health care utilization.
Military veterans with comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) who received topiramate in combination with prolonged exposure therapy (PE) showed greater improvement in PTSD symptoms than those receiving PE alone, a new study has found. The combination treatment did not lead to significant improvement in alcohol use outcomes compared with PE alone. Study results were published online March 19, 2025, in the American Journal of Psychiatry.
Microdosing of lysergic acid diethylamide (LSD) over a 6-week period showed no significant benefits over placebo in reducing symptoms of attention-deficit hyperactivity disorder (ADHD) in adults, a Phase 2A trial has found. Both the LSD and placebo groups experienced marked improvement, the investigators reported.
A systematic review and meta-analysis comprising 27 trials comparing glucagon-like peptide 1 (GLP-1) receptor agonists and placebo in patients with type 2 diabetes or obesity found no significantly increased risk of suicidal behavior in conjunction with the popular medications. The incidence of suicide and self-harm was very low in both the GLP-1 and placebo groups. Results of the review were published online March 19, 2025, in JAMA Psychiatry.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：